Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01633970
Title A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Genentech
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Colorado Cancer Center Aurora Colorado 80045 United States Details
Yale University New Haven Connecticut 06511 United States Details
Georgetown University Medical Center Lombardi Cancer Center Washington District of Columbia 20007 United States Details
Uni of Chicago Chicago Illinois 60637 United States Details
Massachusetts General Hospital. Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Med Ctr Boston Massachusetts 02215 United States Details
Dana Farber Can Ins Boston Massachusetts 02215 United States Details
Laura and ISAAC Perlmutter Cancer Center at NYU Langone. New York New York 10016 United States Details
Duke University Medical Center Durham North Carolina 27705 United States Details
Carolina BioOncology Institute; Can Therapy & Res Ctr Huntersville North Carolina 28078 United States Details
Sarah Cannon Research Inst. Nashville Tennessee 37203 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field